Related Experiment Video
Updated: Feb 18, 2026
14:32
Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates
Published on: February 27, 2016
8.7K
Sirtuin 6, a possible therapeutic target for type 2 diabetes
1College of Pharmacy, Woosuk University, 443 Samnye-ro, Wanju, Jeonbuk, 55338, Republic of Korea. ejbae@woosuk.ac.kr.
Archives of Pharmacal Research
|November 28, 2017
Summary
Sirtuin 6 (SIRT6) plays a complex role in metabolic health. This review explores conflicting findings on SIRT6
Area of Science:
- Molecular Biology
- Metabolic Disease Research
- Genomics
Background:
- Sirtuin 6 (SIRT6) is a nuclear protein regulating chromatin and genomic stability.
- SIRT6 is implicated in metabolic disease, longevity, and cancer.
- Genetic studies suggest SIRT6 activation benefits metabolic homeostasis.
Purpose of the Study:
- To review and reconcile contradictory findings on SIRT6's role in metabolic homeostasis.
- To discuss the therapeutic potential of targeting SIRT6 for type 2 diabetes and related conditions.
Main Methods:
- Literature review of genetic studies and recent pharmacological investigations.
- Analysis of SIRT6's impact on pancreatic insulin secretion, hepatic gluconeogenesis, and adiposity.
- Examination of SIRT6 inhibition effects on glucose tolerance, glycolysis, and glucose transporter expression.
Main Results:
- Genetic evidence indicates SIRT6 activation promotes insulin secretion and inhibits glucose/lipid synthesis, suggesting therapeutic benefits.
- Pharmacological inhibition of SIRT6 improved glucose tolerance in a type 2 diabetes model.
- Conflicting data highlight the complexity of SIRT6's role in metabolic regulation.
Conclusions:
- The precise role of SIRT6 in metabolic homeostasis remains debated.
- Both activation and inhibition of SIRT6 present potential therapeutic avenues for type 2 diabetes.
- Further research is needed to clarify SIRT6's dual role and guide therapeutic strategies.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
1.0K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.0K
01:15Diabetes: Management and Pharmacotherapy
1.1K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.1K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
698
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
698
02:30siRNA - Small Interfering RNAs
18.8K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.8K
01:23Dipeptidyl Peptidase 4 Inhibitors
729
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
729